Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies-Reference-Cited by-同舟云学术

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

Published:2019-02-04 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Kobayashi Roger H.,Gupta Sudhir,Melamed Isaac,Mandujano J. Fernando,Kobayashi Ai Lan,Ritchie Bruce,Geng Bob,Atkinson Thomas Prescott,Rehman Syed,Turpel-Kantor Eva,Litzman Jiří

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference44 articles.

1. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity;Picard;J Clin Immunol.,2018

2. International consensus document (ICON): common variable immunodeficiency disorders;Bonilla;J Allergy Clin Immunol Pract.,2016

3. Practice parameter for the diagnosis and management of primary immunodeficiency;Bonilla;J Allergy Clin Immunol.,2015

4. Subcutaneous administration of IgG;Berger;Immunol Allergy Clin North Am.,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens;Journal of Clinical Immunology;2023-05-09

2. Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience With Enhanced Infusion Regimens;2023-03-24

3. Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies;Frontiers in Immunology;2022-12-20

4. Cutaquig® Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products;Hematology Reports;2022-11-17

5. Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency;Expert Review of Clinical Immunology;2022-11-15